Skip to main content

Table 2 Cure ratesa in studies for female and male patients with urgency urinary incontinence

From: Can incontinence be cured? A systematic review of cure rates

Follow-up:

3 m

6 m

12 m

18 m

2 y

3 y

5 y

Treatment – WOMEN

Antimuscarinic

 

21%

     

Darifenacinb

38%

41%

42%

 

43.8%

  

Fesoterodine

63%; 62%; 64%; 49.2%; 57.8%

      

Oxybutynin

25.2%; 20%

      

Solifenacin

58%; 59%; 56.2%; 59.6%

11%

58%

    

Tolterodine

13%; 56%

57.2%; 49%

70%

45.1%

    

Tolterodine + BI

 

NR

     

Trospium

35.6%; 20.5%

      

Adrenergic drugs (Mirabegron)

47.1%

 

43.4%; 45.8%

    

Neuromodulation

 

39%

    

15% (10 y: 17%)

Neuromodulation + PFMR

93%

39%

    

15% (10 y: 17%)

TVT

 

92%

     

Botulinum toxin

35%; 22.9%

15.9–50.9%

31.3%

     

Treatment – MEN

Solifenacin + Tamsulosin

NR

      

PFMT – supervised

  

24%; 35%

    

Lifestyle advice – unsupervised

  

23%; 38%

    
  1. aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’, or complete continence
  2. bReductions of ≥ 90% from feeder-study baseline in incontinence episodes/week
  3. BI behavioral interventions; NR not reported; PFMT pelvic floor muscle training; TVT tension-free vaginal tape
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us